Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.78 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752591 | 0.91 | PIK3CA (0.80) | PIK3CAGPR142PRKDC | |
| SCHEMBL3757862 | 0.90 | PIK3CA (0.72) | PIK3CAGPR142PRKDCLMNASMN1; SMN2 | |
| SCHEMBL3752201 | 0.90 | PIK3CA (0.80) | PIK3CAPRKDCCREBBP | |
| Hydrochloric Acid SCHEMBL3765849 | 0.89 | PIK3CA (0.71) | PIK3CAGPR142PRKDCLMNASMN1; SMN2 | |
| SCHEMBL3756510 | 0.87 | PIK3CA (1.00) | PIK3CAPRKDCCREBBPKDM4E | |
| SCHEMBL3757877 | 0.85 | PIK3CA (0.64) | PIK3CAGPR142PRKDCCREBBP | |
| SCHEMBL3749683 | 0.84 | PIK3CA (0.72) | PIK3CAPRKDCCREBBPKDM4E | |
| SCHEMBL3755539 | 0.83 | PIK3CA (0.80) | PIK3CAPRKDCCREBBP | |
| SCHEMBL3749636 | 0.82 | PIK3CA (0.70) | PIK3CAPRKDCCREBBP | |
| SCHEMBL3756614 | 0.82 | PIK3CA (1.00) | PIK3CAGPR142PRKDCCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PIK3CA 16/4885GPR142 4122/4885PRKDC 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.